From the Division of Neuroradiology (A.B., R.K., M.K., A.S.), Department of Radiology, University of Michigan, Ann Arbor, Michigan
Department of Radiology (A.B.), The Jikei University School of Medicine, Tokyo, Japan.
AJNR Am J Neuroradiol. 2023 Oct;44(10):1184-1190. doi: 10.3174/ajnr.A7992. Epub 2023 Sep 14.
The Neck Imaging Reporting and Data System (NI-RADS) is a reporting template used in head and neck cancer posttreatment follow-up imaging.
Our aim was to evaluate the pooled detection rates of the recurrence of head and neck squamous cell carcinoma based on each NI-RADS category and to compare the diagnostic accuracy between NI-RADS 2 and 3 cutoffs.
The MEDLINE, Scopus, and EMBASE databases were searched.
This systematic review identified 7 studies with a total of 694 patients (1233 lesions) that were eligible for the meta-analysis.
The meta-analysis of pooled recurrence detection rate estimates for each NI-RADS category and the diagnostic accuracy of recurrence with NI-RADS 3 or 2 as the cutoff was performed.
The estimated recurrence rates in each category for primary lesions were 74.4% for NI-RADS 3, 29.0% for NI-RADS 2, and 4.2% for NI-RADS 1. The estimated recurrence rates in each category for cervical lymph nodes were 73.3% for NI-RADS 3, 14.3% for NI-RADS 2, and 3.5% for NI-RADS 1. The area under the curve of the summary receiver operating characteristic for recurrence detection with NI-RADS 3 as the cutoff was 0.887 and 0.983, respectively, higher than 0.869 and 0.919 for the primary sites and cervical lymph nodes, respectively, with NI-RADS 2 as the cutoff.
Given the heterogeneity of the data of the studies, the conclusions should be interpreted with caution.
This meta-analysis revealed estimated recurrence rates for each NI-RADS category for primary lesions and cervical lymph nodes and showed that NI-RADS 3 has a high diagnostic performance for detecting recurrence.
颈部成像报告和数据系统(NI-RADS)是头颈部癌症治疗后随访成像中使用的报告模板。
我们的目的是评估根据每个 NI-RADS 类别对头颈部鳞状细胞癌复发的汇总检测率,并比较 NI-RADS 2 和 3 截止值之间的诊断准确性。
检索了 MEDLINE、Scopus 和 EMBASE 数据库。
这项系统评价确定了 7 项研究,共有 694 名患者(1233 个病变)符合荟萃分析的条件。
对每个 NI-RADS 类别汇总的复发检测率估计值和使用 NI-RADS 3 或 2 作为截止值的复发的诊断准确性进行了荟萃分析。
原发性病变每个类别估计的复发率分别为 NI-RADS 3 为 74.4%,NI-RADS 2 为 29.0%,NI-RADS 1 为 4.2%。颈部淋巴结每个类别估计的复发率分别为 NI-RADS 3 为 73.3%,NI-RADS 2 为 14.3%,NI-RADS 1 为 3.5%。NI-RADS 3 作为截止值时,复发检测的汇总受试者工作特征曲线下面积分别为 0.887 和 0.983,均高于原发性病变和颈部淋巴结分别以 NI-RADS 2 作为截止值时的 0.869 和 0.919。
鉴于研究数据的异质性,应谨慎解释结论。
这项荟萃分析揭示了原发性病变和颈部淋巴结每个 NI-RADS 类别的估计复发率,并表明 NI-RADS 3 对检测复发具有较高的诊断性能。